News
📈 Stocks
Akeso Receives NMPA Priority Review for Ivonescimab in Biliary Tract Cancer
(3 days ago)
Akeso's ivonescimab secures NMPA Priority Review status for first-line biliary tract cancer treatment, marking a potential regulatory milestone for the company's lead…